Busulfan/cytarabine/melphalan

Abstract

Busulfan/cytarabine/melphalan Respiratory distress syndrome: case reportIn a retrospective study of 177 patients, who received conditioning treatment before autologous haematopoietic stem cell transplantation (ASCT) between 2000 and 2015, an adult patient [sex and exact age not stated] was described, who developed respiratory distress syndrome during treatment with busulfan, cytarabine and melphalan [routes and dosages not stated].The patient had lymphoma, and ASCT was scheduled. The patient received conditioning therapy with busulfan, cytarabine [aracytine] and melphalan, and the patient underwent the ASCT. The patient developed toxicity in the form of respiratory distress syndrome secondary to busulfan, cytarabine and melphalan, and died within 100 days from the ASCT [duration of treatment to reaction onset not stated].